RecruitingPHASE1, PHASE2NCT06876363
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
Studying Chronic granulomatous disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ensoma
- Intervention
- EN-374(genetic)
- Enrollment
- 15 enrolled
- Eligibility
- MALE
- Timeline
- 2025 – 2027
Study locations (9)
- University of California, Los Angeles, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Columbia University Irving Medical Center, Morgan Stanley Children's Hospital, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- University of Utah, Primary Children's Hospital, Salt Lake City, Utah, United States
- University College London Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06876363 on ClinicalTrials.govOther trials for Chronic granulomatous disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07284641Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)Paul Szabolcs
- ENROLLING BY INVITATIONPHASE1NCT07113743Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06605378Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous DiseaseEnsoma
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06559176A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )Prime Medicine, Inc.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06253507pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)National Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1NCT06325709Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05600907Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)National Institute of Allergy and Infectious Diseases (NIAID)
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT05104723Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsNational Institute of Allergy and Infectious Diseases (NIAID)